Sheila Gujrathi, Director and Chief Strategy Officer of Bolt Biotherapeutics, Inc., filed a Form 4 on October 27, 2026, reporting the acquisition of common stock and Series D Convertible Preferred Stock on October 23, 2026, as merger consideration from the company's acquisition of Prana Therapies, Inc.

Key Highlights

  • Merger date: The transaction closed on October 23, 2026, under an Agreement and Plan of Merger among Bolt Biotherapeutics, Prana Therapies, Prince Merger Sub I, Inc., and Prince Merger Sub II, LLC.
  • Exchange ratio: Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of Bolt Biotherapeutics common stock or common-stock equivalents.
  • Direct holdings acquired: Gujrathi directly received 72,766 shares of common stock and 2,763.833 shares of Series D Preferred Stock, both at a price of $0.
  • Indirect holdings acquired: SilverArc Private Fund I, L.P. received 13,055 shares of common stock and 495.874 shares of Series D Preferred Stock, also at a price of $0.
  • Conversion terms: Each share of Series D Preferred is convertible into 1,000 shares of Bolt Biotherapeutics common stock, subject to conditions including receipt of requisite stockholder approval, and has no expiration date.
  • Disclaimer: Gujrathi disclaims beneficial ownership of securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein, according to the filing.

Bolt Biotherapeutics Merger Converts Prana Holdings for Gujrathi

According to the Form 4 filed with the SEC on October 27, 2026, Sheila Gujrathi, serving as both Director and Chief Strategy Officer of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), reported changes in her beneficial ownership resulting from the closing of the merger with Prana Therapies, Inc. on October 23, 2026. The filing describes the transaction as occurring pursuant to an Agreement and Plan of Merger dated October 23, 2026, involving Bolt Biotherapeutics, Prana Therapies, wholly owned subsidiary Prince Merger Sub I, Inc. (a Delaware corporation), and wholly owned subsidiary Prince Merger Sub II, LLC (a Delaware limited liability company).

Under the merger terms as disclosed in the filing, each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of Bolt Biotherapeutics common stock or common-stock equivalents. These equivalents consisted of Bolt common stock and Series D Convertible Preferred Stock, with each share of Series D Preferred convertible at a rate of 1,000 shares of common stock per share of Series D Preferred. The filing states that no cash purchase price was paid for the Series D Preferred received as merger consideration.

Gujrathi's Prana shares held directly converted into 72,766 shares of Bolt common stock and 2,763.833 shares of Series D Preferred, both acquired at $0. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of common stock and 495.874 shares of Series D Preferred, also at $0. The filing notes that Gujrathi is Co-Portfolio Manager and holds membership interest in entities that serve as the Ultimate General Partner, General Partner, and Management Company for SilverArc Private Fund I, L.P., but states she "may not be deemed to have voting or investment power over the shares held of record" by that fund.

What Was Disclosed

Sheila Gujrathi filed a Form 4 reporting acquisition of Bolt Biotherapeutics common stock and Series D Convertible Preferred Stock on October 23, 2026, as merger consideration from the Prana Therapies acquisition, with both direct and indirect holdings reported at a $0 price.